File(s) stored somewhere else
Please note: Linked content is NOT stored on University of Illinois at Chicago and we can't guarantee its availability, quality, security or accept any liability.
Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development
journal contributionposted on 06.05.2022, 15:51 by Tina L Mistry, Lena Truong, Arun K Ghosh, Michael JohnsonMichael Johnson, Shahila Mehboob
The enoyl-ACP reductase (FabI) enzyme is a well validated target for anti-staphylococcal drug discovery and development. With the goal of finding alternate therapeutics for drug-resistant strains of Staphylococcus aureus, such as methicillin-resistant S. aureus (MRSA), our previously published series of benzimidazole-based inhibitors of the FabI enzyme from Francisella tularensis (FtFabI) have been evaluated against FabI from S. aureus (SaFabI). We report here the preliminary structure-activity relationship of this series and the prioritization of compounds toward lead optimization. Mutational studies have identified key residues that contribute toward stabilizing the inhibitors in the active site of FabI. Mutations that do not significantly impact enzyme function but destabilize inhibitor binding are more likely to occur in nature as organisms evolve to evade the action of antibiotics leading to resistance. Identifying these residues provides guidance for minimizing susceptibility to resistance. Additionally, we have identified compounds that elicit antibacterial activity through off-target effects and observe that close analogs can display differing modes of action (on-target vs off-target) and need to be individually evaluated early on to prioritize compounds for lead optimization. Overall, our data suggest that the benzimidazole scaffold is a promising scaffold for anti-staphylococcal drug development.
Novel Antibiotic Development For Biodefense | Funder: National Institutes of Health (National Institute of Allergy and Infectious Diseases) | Grant ID: U01AI077949
Development of novel dual-mode antibiotics for drug resistant S. aureus | Funder: National Institute of Allergy and Infectious Diseases | Grant ID: R41AI110090
CitationMistry, T. L., Truong, L., Ghosh, A. K., Johnson, M. E.Mehboob, S. (2016). Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development. ACS Infectious Diseases, 3(1), 54-61. https://doi.org/10.1021/acsinfecdis.6b00123
PublisherAmerican Chemical Society (ACS)
Read the peer-reviewed publication
BiodefenseVaccine RelatedEmerging Infectious DiseasesPreventionAntimicrobial ResistanceInfectious DiseasesBiotechnology5.1 PharmaceuticalsInfectionStaphylococcus aureusFabIbenzimidazole inhibitorenoyl-ACP reductasemode of actionAnti-Bacterial AgentsBenzimidazolesCloning, MolecularDrug DesignDrug DiscoveryEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Gene Expression Regulation, BacterialGene Expression Regulation, EnzymologicInhibitory Concentration 50Molecular StructureStructure-Activity RelationshipMedical Microbiology